In this blog, we explore the growing concerns about fraudulent RCTs highlighted in a recent Nature article. Discover how innovative risk management approaches can detect, prevent, and tackle these issues, facilitating more robust regulatory oversight.
MyRBQM Portal has made its debut on the Azure Marketplace. This milestone allows biopharmaceutical companies to streamline and unify their approach to risk management by using the secure and reliable Azure cloud platform.
How heavily do decentralized clinical trials rely on technology? We asked Craig Lipset, a leading expert in the field of decentralized clinical trials.
Discover how Decentralized Clinical Trials (DCTs) have the potential to reshape oncology care. Using our eyesON DCT Outlook, we reveal how patient demographics, broadband internet, and registered oncologists could drive DCT opportunities and potentially enhance cancer survivorship.
Data visualization tool designed to identify untapped opportunities for Decentralized Clinical Trials advancement in the oncology sector in the USA.
Be prepared for ICH E6(R3): turn guidelines into real-world action. In this post, we delve into the key updates and training gaps.
Unpacking the new ICH guidelines, E6(R3) and E8(R1), we illuminate their key elements, identify gaps, and compare the two in terms of their unity, differences, and complementarity.
Dive into the FDA's latest draft guidance on Decentralized Clinical Trials and the role of Risk-Based Quality Management. Learn how RBQM and centralized monitoring can elevate your clinical research efficiency and reliability.
Big Pharma M&As: A Worthwhile Challenge? Navigating the complex landscape of M&As in the pharmaceutical industry comes with unique objectives and potential benefits. But do these transactions truly drive shareholder value for the acquiring firm?
Navigate your M&A journey confidently with Cyntegrity's MyRBQM Portal. Aspiring to hit your targets within 6-12 months? Discover how we can make it possible in R&D due diligence.
